Prohibitin-targeting peptide (experimental fat-vasculature ligand)
Adipotide
Designed peptide intended to bind prohibitin-expressing vasculature in white adipose tissue and deliver a pro-apoptotic sequence in animal models.
Primary Mechanism of Action
Clinical / Scientific
Adipotide (CKGGRAKDC-GG-D(KLAKLAK)2 class constructs) was designed to homing-peptide target prohibitin on adipose vasculature and induce disruption in those endothelial cells in rodents. Human development did not yield an approved drug.
Pathway Targets
Prohibitin (adipose vasculature)
Scientific explanation
Targeting ligand in experimental constructs.
Apoptosis
Scientific explanation
Pro-apoptotic payload in targeted endothelium (models).
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: Prohibitin (adipose vasculature) → Apoptosis
Mechanistically Relevant Repurposed & Adjunctive Applications
Research peptide context
PreclinicalMechanistic rationale
Catalogued as a research peptide. Mechanistic statements below describe known or pathway biology and do not establish a licensed therapeutic indication.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| Prohibitin | Targeted binding | Adipose vasculature in models | Preclinical |
In Plain Language
Adipotide was a research peptide meant to find blood vessels that feed fat tissue and trigger those vessel cells to die in animals. It is not an approved fat-loss drug.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
Apoptosis
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.